GlassScriptPhysician profile
John A Saia
NPI 1346229911
$6,082.87
in general payments reported to CMS, 2019-2025
29 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $599 · 2021: $1,673 · 2022: $587 · 2023: $706 · 2024: $777 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,214.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $852.95 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $563.34 | 2021-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $550.59 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $550.42 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $457.78 | 2019-2023 | |
| Amgen INC. | $438.14 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $436.73 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $428.08 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $298.77 | 2019-2025 | Farxiga |
| Merck Sharp & Dohme LLC | $237.64 | 2021-2025 | Verquvo |
| Pfizer INC. | $185.96 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $158.62 | 2019-2021 | |
| Boston Scientific Corporation | $151.44 | 2022-2025 | Watchman Access System, General - Therapies, Watchman Flx |
| Abiomed | $112.18 | 2024-2025 | Impella |
| Regeneron Healthcare Solutions, INC. | $101.74 | 2019-2024 | Evkeeza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.57 | 2021-2024 | Lifevest |
| Arbor Pharmaceuticals, INC. | $65.17 | 2019-2021 | |
| Medtronic, INC. | $56.98 | 2024 | Symplicity G3 |
| W. L. Gore & Associates, INC. | $50.15 | 2020-2021 | |
| Heartflow, INC. | $50.08 | 2024 | |
| Cvrx, INC. | $49.17 | 2024 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $48.40 | 2023-2024 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $35.57 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $34.11 | 2024-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $25.28 | 2019-2021 | |
| Inspire Medical Systems, INC. | $22.12 | 2024 | Inspire |
| Edwards Lifesciences Corporation | $20.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $14.24 | 2022 | |
| Gilead Sciences, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Saia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.